查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096643

HIV臨床試驗市場－2026-2032年全球市場預測

HIV Clinical Trials Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，愛滋病臨床試驗市場將成長至 23.4 億美元，複合年成長率為 5.65%。

主要市場統計數據
基準年 2025 15.9億美元
預計年份：2026年 16.8億美元
預測年份 2032 23.4億美元
複合年成長率 (%) 5.65%

隨著全球研究重點從逐步最佳化抗逆轉錄病毒療法轉向長效預防、廣譜中和抗體、治療性疫苗、基於免疫的策略以及旨在治癒愛滋病的干預措施，愛滋病臨床試驗正進入關鍵階段。臨床研發的趨勢受到愛滋病持續存在的公共衛生負擔、對更具包容性的受試者群體的需求以及對能夠提高藥物依從性、減少歧視和解決抗藥性的治療方案日益成長的需求等因素的影響。根據國際公共衛生組織統計，全球有數千萬人感染愛滋病毒，而預防、診斷延遲和治療可近性的差距仍在影響著臨床試驗點的設計和選擇。因此，愛滋病臨床試驗越來越重視真實世界的可行性、社區參與、藥物動力學多樣性、孕婦和青少年的參與以及受愛滋病影響人群的代表性，包括男男性行為者、跨性別者、注射毒品者、性工作者和高感染地區的社區。

正在重塑愛滋病臨床試驗的變革性變化

愛滋病臨床試驗的變革性變化源自於科學創新、監管現代化以及對公平性的日益重視。長效注射劑和植入式預防藥物正在改變人們對以藥物依從性為重點的試驗終點的預期，而口服和注射暴露前預防（PrEP）的研究也擴大評估差異化的給藥模式和特定人群的接受度。治癒研究正透過潛伏期逆轉劑、免疫查核點調節、基因編輯概念、基於幹細胞的方法以及聯合免疫療法策略不斷擴展，但安全性、永續性和擴充性仍然是核心挑戰。臨床試驗方案也在不斷發展，納入了分散式訪視、遠端監測、電子知情同意（eConsent）、用於支持藥物依從性的行動醫療醫療工具以及社區主導的受試者招募，尤其是在那些因污名化和行動障礙而限制參與的地區。監管機構和倫理委員會更加重視受試者保護、試驗後取得途徑、知情同意的品質以及在科學合理的情況下孕婦和哺乳期婦女的參與。這些變化正在將愛滋病毒臨床研究從以機構為中心的實驗轉變為更具適應性、以受試者為中心的開發計畫。

人工智慧對愛滋病臨床試驗的累積影響

人工智慧 (AI) 透過方案設計、受試者識別、風險分層、藥物安全監測和提高營運效率，對 HIV 臨床試驗的影響日益顯著。機器學習模型能夠幫助研究人員分析流行病學模式、病毒遺傳多樣性、抗藥性光譜、用藥依從性以及合併感染風險，從而設計更具針對性和更全面的研究。在隱私法規允許的情況下，自然語言處理可以加速電子健康記錄的篩檢；預測分析則可以識別出受試者招募可行性高且持續參與可能性高的研究中心。人工智慧驅動的成像、數位生物標記以及來自穿戴式裝置的資料流也有助於安全監測和用藥依從性評估。然而，人工智慧的累積影響取決於數據品質、透明的檢驗、偏差緩解、網路安全以及對臨床研究法規的遵守。在 HIV 臨床試驗中，由於這些試驗通常涉及弱勢群體，因此負責任的人工智慧管治至關重要，它可以防止演算法排除受試者、保護受試者隱私，並確保在不損害信任的前提下促進數位創新。

全球愛滋病臨床試驗的關鍵區域性見解

由於亞太地區人口眾多、流行模式多樣且臨床研究基礎設施不斷完善，該地區在愛滋病臨床試驗中的重要性日益凸顯。中國、印度、日本、韓國和澳洲在藥物研發、免疫學、預防和監管科學方面各具優勢。歐洲在多邊試驗協調、藥物安全監測系統、倫理監管和轉化研究方面擁有強大的能力，尤其注重隊列研究、抗藥性監測、差異化治療模式和統一的臨床試驗流程。北美仍然是早期和晚期愛滋病研究的領先中心，這得益於其先進的試驗網路、完善的監管流程、廣泛的檢測能力以及在長效療法、預防研究和以治愈為導向的研究方面積累的豐富經驗。拉丁美洲在預防和治療試驗中發揮著越來越重要的作用，尤其是在都市區愛滋病感染率高、擁有社區醫療保健網路以及以往在感染疾病研究方面積累的經驗，這些都為受試者招募和真實世界實施研究提供了支持。非洲在全球愛滋病負擔中佔相當大的比例，並且一直是全球愛滋病臨床試驗的中心樞紐，為預防、最佳化治療、孕產婦健康、青少年愛滋病、感染疾病以及高發地區的實施策略提供了重要的科學見解。在中東，由於對醫療基礎設施的投資和集中式專科護理的發展，臨床試驗能力正在逐步擴大，但污名化、診斷差異和跨境監管差異正在影響受試者的招募。

深入了解影響愛滋病臨床研究的關鍵群體

北約成員國，其中許多是發達的研究型經濟體，透過其臨床基礎設施為愛滋病臨床試驗的穩健開展做出貢獻，尤其是在生物醫學安全優先事項、感染疾病防範、跨境協調和監管信譽至關重要的領域。七國集團（G7）憑藉其先進的監管體系、檢測能力、資金籌措環境以及在複雜試驗設計（包括長效藥物、免疫療法和治癒性研究）方面的經驗，繼續對愛滋病臨床研究產生重大影響。金磚國家（巴西、俄羅斯、印度、中國和南非）在藥物可及性、抗菌素抗藥性、預防推廣、感染疾病和實施科學方面各有所長，它們共同代表著龐大且多元化的患者群體，不斷擴展的生物醫學研究能力以及重要的公共衛生意義。歐盟支持臨床試驗法規的協調統一、跨境倫理協調、藥物安全監測標準以及對愛滋病治療、預防和安全研究特別重要的多邊合作研究網路。由於重點族群中愛滋病疫情集中爆發、公共衛生計畫不斷擴展以及科研管治水準的提高，東南亞國協在愛滋病臨床試驗中的重要性日益凸顯，這些因素為以預防、診斷和藥物依從性為重點的研究創造了機會。海灣合作理事會（GCC）地區擁有先進的醫療基礎設施，不斷加大對臨床研究的投入，並採用集中式醫療模式，但愛滋病相關的社會污名以及確診患者數量較少，使得精心設計的受試者招募策略和保密措施顯得尤為重要。

各國對愛滋病臨床試驗開展情況的深入了解。

中國憑藉大規模的臨床基礎設施、生物醫學創新以及在抗病毒研究領域日益成長的參與度，正在擴大其在愛滋病臨床試驗中的作用。同時，美國憑藉其廣泛的學術試驗網路、監管專長、社區諮詢框架以及專注於預防、長效療法、抗藥性和治癒策略的研究，成為領先的研究環境。日本在先進的監管科學、免疫學研究和高品質的臨床管理方面做出了貢獻，而印度則擁有豐富的科學基礎、大規模的患者群體以及在學名藥、診斷和公共衛生政策實施方面的經驗。德國、英國、法國、義大利和西班牙擁有成熟的臨床研究體系、愛滋病專科中心和歐洲內部合作，並在藥物安全監測、抗藥性監測、轉化醫學和基於隊列的證據生成方面擁有強大的能力。澳洲以其強大的愛滋病預防調查、社區參與和可操作的試驗設計而聞名，而韓國則憑藉其先進的醫院網路、數位醫療能力和不斷擴展的感染疾病研究能力，正在加強亞太地區在全球愛滋病臨床試驗中的參與度。加拿大在進行穩健的世代研究、與公共衛生體系的整合以及重點族群研究方面擁有豐富的經驗。俄羅斯雖然在愛滋病流行病學領域仍舉足輕重，但在感染疾病和治療取得方面仍面臨諸多挑戰，並且可能受到監管和地緣政治因素的阻礙，從而阻礙其參與國際臨床試驗。巴西在愛滋病治療基礎設施和研究方面擁有悠久的歷史和豐富的經驗，在拉丁美洲的預防、治療和實施研究中發揮著至關重要的作用。墨西哥憑藉其都市區愛滋病護理網路和跨境公共衛生的考量，強調了本地招募受試者的重要性。

為愛滋病臨床試驗負責人提供的實用建議

產業領導者應優先考慮全面的方案設計、以科學論證的方式納入代表性不足的人群，並儘早與區域諮詢小組開展合作，以提高信心、招募和保留參與者的比率。臨床實驗申辦方和研究人員應定義符合真實世界愛滋病治療需求的終點，包括藥物依從性、耐受性、耐受性結果、藥物交互作用、懷孕期間的安全性以及治療療效持續時間。應有選擇地實施分散式臨床實驗工具，並採取強力的措施來保護隱私、提高數位素養和維護參與者的保密性。領導者應投資於區域試驗點的準備工作、檢查室品管系統、人員培訓和倫理審查能力，尤其是在高負擔地區，因為這些地區的研究參與和試驗後獲取計劃必須保持一致。人工智慧驅動的工具在部署前應在不同人群中進行檢驗，管治框架必須解決偏倚、可解釋性、網路安全和資料保護法規合規性問題。與公共衛生計畫、社區團體和監管相關人員建立策略夥伴關係可以提高可行性，同時支持設計科學嚴謹、對社會負責且運作穩健的臨床試驗。

從實證愛滋病臨床試驗中獲得見解的調查方法

本執行摘要採用系統性的二手研究途徑，利用檢驗的公共衛生、監管、科學和臨床試驗資訊來源編寫而成。調查方法包括：對經認可的公共衛生機構發布的全球愛滋病流行病學數據進行審查；對臨床試驗註冊庫進行趨勢分析；評估有關開展臨床研究的監管指南；以及整合與抗逆轉錄病毒藥物研發、愛滋病預防、疫苗研究、免疫療法和以治愈為導向的治療方法相關的同行議文獻。透過疾病負擔、臨床研究基礎設施、監管成熟度、公共衛生計畫能力和重點人群代表性等已記錄的指標，對區域、群體和國家層面的見解進行解讀。本分析不涉及市場規模、市場佔有率、收入估算和預測；而是著重於基於證據的定性趨勢、科學重點、營運趨勢以及影響愛滋病臨床試驗的政策相關發展。

關於愛滋病臨床試驗未來的結論

愛滋病臨床試驗的進展得益於生物醫學創新、數位轉型、不斷完善的監管以及以社區為中心的研究實踐的改進。該領域正從比較療法轉向以治癒為導向的策略，這需要長效預防、差異化給藥、免疫干預以及包含多樣化參與者的複雜試驗設計。地域參與範圍正在擴大，愛滋病高流行地區、已開發的研究經濟體和新興的臨床研究中心提供了重要的證據。雖然人工智慧和去中心化技術可以提高效率和準確性，但它們的價值取決於倫理管治、包容性和在所有愛滋病感染人群中檢驗的性能。愛滋病臨床研究的下一階段將取決於相關人員如何整合科學嚴謹性和公平性、營運適應性以及對參與者信任和公共衛生影響的持續承諾。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 HIV臨床試驗市場：依藥物類別分類

  • 入侵抑制劑
    • 恩氟維替德
    • 馬拉威羅克
  • 整合酶/鏈轉移抑制劑
    • 比克替拉韋
    • 多替拉韋
    • 埃爾維特格拉維爾
    • 拉特格拉維爾
  • 非核苷類逆轉錄酶抑制劑
    • 依非韋倫
    • 依福西林
    • 奈韋拉平
    • 利匹韋林
  • 核苷類逆轉錄酶抑制劑
    • 恩曲他濱
    • 拉米夫定
    • 替諾福韋
    • 齊多夫定
  • 蛋白酶抑制劑
    • 阿扎那韋
    • 達蘆那韋
    • 福斯帕奈韋
    • 洛匹那韋

第8章：愛滋病臨床試驗市場：依臨床試驗階段分類

  • 第一階段
  • 第二階段
    • 第二階段a
    • IIb期
  • 第三階段
  • 第四階段

第9章：愛滋病臨床試驗市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 經皮給藥

第10章：愛滋病臨床試驗市場：依病患年齡層別分類

  • 成人
  • 老年人
  • 兒童

第11章 HIV臨床試驗市場：依最終使用者分類

  • 診所
  • 醫院
  • 研究機構
    • 學術機構
    • 受託研究機構

第12章 HIV臨床試驗市場：依通路分類

  • 離線
  • 線上

第13章：愛滋病臨床試驗市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章 HIV臨床試驗市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章 愛滋病臨床試驗市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • American Gene Technologies International Inc.
  • Assembly Biosciences, Inc.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Charles River Laboratories International, Inc.
  • CytoDyn Inc.
  • Excision BioTherapeutics, Inc.
  • Frontier Biotechnologies Inc.
  • GeoVax Labs, Inc.
  • Gilead Sciences, Inc.
  • IAVI
  • ICON plc
  • International AIDS Vaccine Initiative, Inc.
  • IQVIA Holdings Inc.
  • Johnson & Johnson
  • Labcorp Drug Development Inc.
  • Medpace Holdings, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novotech Health Holdings Pte. Ltd.
  • Parexel International Corporation
  • PPD, Inc.
  • Shanghai Henlius Biotech, Inc.
  • Syneos Health, Inc.
  • TaiMed Biologics Inc.
  • Theratechnologies Inc.
  • ViiV Healthcare Limited
  • Vir Biotechnology, Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-7C50F273957B

The HIV Clinical Trials Market is projected to grow by USD 2.34 billion at a CAGR of 5.65% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.59 billion
Estimated Year [2026] USD 1.68 billion
Forecast Year [2032] USD 2.34 billion
CAGR (%) 5.65%

HIV clinical trials are entering a decisive phase as global research priorities shift from incremental antiretroviral optimization toward long-acting prevention, broadly neutralizing antibodies, therapeutic vaccines, immune-based strategies, and potential cure-directed interventions. The clinical development landscape is shaped by the persistent public health burden of HIV, the need for more inclusive trial populations, and the growing demand for regimens that improve adherence, reduce stigma, and address drug resistance. According to international public health agencies, tens of millions of people are living with HIV globally, with prevention gaps, late diagnosis, and unequal access to treatment continuing to influence trial design and site selection. As a result, HIV clinical trials increasingly emphasize real-world feasibility, community engagement, pharmacokinetic diversity, pregnancy and adolescent inclusion, and representation of populations disproportionately affected by HIV, including men who have sex with men, transgender people, people who inject drugs, sex workers, and communities in high-incidence regions.

Transformative Shifts Reshaping HIV Clinical Trials

Transformative shifts in HIV clinical trials are being driven by scientific innovation, regulatory modernization, and a stronger focus on equity. Long-acting injectable and implantable prevention approaches have changed expectations for adherence-focused trial endpoints, while oral and injectable pre-exposure prophylaxis studies increasingly evaluate differentiated delivery models and population-specific acceptability. Cure research is expanding through latency-reversing agents, immune checkpoint modulation, gene editing concepts, stem-cell-based approaches, and combination immunotherapy strategies, although safety, durability, and scalability remain central challenges. Trial protocols are also evolving to include decentralized visits, remote monitoring, eConsent, mobile health adherence tools, and community-led recruitment, particularly where stigma and travel barriers limit participation. Regulators and ethics bodies are placing greater emphasis on participant protection, post-trial access, informed consent quality, and inclusion of pregnant and lactating people when scientifically justified. These shifts are transforming HIV clinical research from site-centered experimentation into more adaptive, participant-centered development programs.

Cumulative Impact of Artificial Intelligence on HIV Clinical Trials

Artificial intelligence is increasingly influencing HIV clinical trials by improving protocol design, participant identification, risk stratification, pharmacovigilance, and operational efficiency. Machine learning models can support analysis of epidemiological patterns, viral genetic diversity, resistance profiles, adherence behavior, and co-infection risks, helping investigators design more targeted and inclusive studies. Natural language processing can accelerate screening of electronic health records where permitted by privacy regulations, while predictive analytics can identify sites with stronger recruitment feasibility and retention potential. AI-enabled imaging, digital biomarkers, and wearable data streams may also contribute to safety monitoring and behavioral adherence assessment. However, the cumulative impact of AI depends on data quality, transparent validation, bias mitigation, cybersecurity, and compliance with clinical research regulations. In HIV clinical trials, where marginalized populations are often involved, responsible AI governance is essential to prevent algorithmic exclusion, protect confidentiality, and ensure that digital innovation strengthens rather than undermines trust.

Key Regional Insights Across Global HIV Clinical Trials

Asia-Pacific is becoming increasingly important for HIV clinical trials due to its demographic scale, diverse epidemic patterns, and expanding clinical research infrastructure, with China, India, Japan, South Korea, and Australia contributing distinct strengths across drug development, immunology, prevention, and regulatory science. Europe contributes strong multicountry trial coordination, pharmacovigilance systems, ethics oversight, and translational research capabilities, with emphasis on cohort science, resistance surveillance, differentiated care models, and harmonized clinical trial procedures. North America remains a major hub for early- and late-stage HIV studies supported by advanced trial networks, established regulatory pathways, extensive laboratory capacity, and strong experience in long-acting therapeutics, prevention studies, and cure-directed research. Latin America plays a growing role in prevention and treatment trials, particularly where urban HIV incidence, community health networks, and prior experience in infectious disease research support participant recruitment and real-world implementation studies. Africa remains central to global HIV clinical trials because it carries a substantial share of the global HIV burden and provides essential scientific insight into prevention, treatment optimization, maternal health, adolescent HIV, co-infections, and implementation strategies across high-incidence settings. The Middle East is seeing gradual expansion in clinical trial capacity, supported by investments in healthcare infrastructure and centralized specialist care, though stigma, diagnosis gaps, and cross-border regulatory variation affect recruitment.

Key Group Insights Influencing HIV Clinical Research

NATO member countries, many of which overlap with advanced research economies, contribute through biomedical security priorities, infectious disease preparedness, and clinical infrastructure that can support robust HIV trial conduct, especially where cross-border coordination and regulatory reliability are essential. G7 countries remain influential in HIV clinical research through advanced regulatory systems, laboratory capabilities, funding ecosystems, and experience with complex trial designs, including long-acting agents, immune therapies, and cure research. BRICS countries collectively bring large and diverse patient populations, expanding biomedical research capacity, and significant public health relevance, with Brazil, Russia, India, China, and South Africa contributing different insights into access, resistance, prevention uptake, co-infections, and implementation science. The European Union supports harmonized clinical trial regulation, cross-border ethics coordination, pharmacovigilance standards, and collaborative research networks that are particularly valuable for multicountry HIV treatment, prevention, and safety studies. ASEAN countries are increasingly relevant for HIV clinical trials because concentrated epidemics among key populations, expanding public health programs, and improving research governance create opportunities for prevention, diagnostics, and adherence-focused studies. The GCC region offers advanced healthcare infrastructure, growing clinical research investment, and centralized care models, but HIV-related stigma and smaller diagnosed patient pools require carefully designed recruitment strategies and confidentiality safeguards.

Key Country Insights for HIV Clinical Trial Development

China is expanding its role in HIV clinical trials through large-scale clinical infrastructure, biomedical innovation, and growing participation in antiviral research, while the United States is a leading environment due to its extensive academic trial networks, regulatory expertise, community advisory structures, and research focus on prevention, long-acting therapy, resistance, and cure strategies. Japan contributes advanced regulatory science, immunology research, and high-quality clinical operations, while India offers substantial scientific capacity, large patient populations, and experience in generics, diagnostics, and public health implementation. Germany, the United Kingdom, France, Italy, and Spain provide mature clinical research systems, specialist HIV centers, and multicountry European collaboration, with strong capabilities in pharmacovigilance, resistance monitoring, translational medicine, and cohort-based evidence generation. Australia is recognized for strong HIV prevention research, community engagement, and pragmatic trial design, while South Korea adds advanced hospital networks, digital health capability, and growing infectious disease research capacity, strengthening Asia-Pacific participation in global HIV clinical trials. Canada contributes strong cohort studies, public health integration, and expertise in key population research, while Russia remains relevant due to HIV epidemiology, co-infection concerns, and treatment access challenges, although regulatory and geopolitical factors can affect international trial participation. Brazil has long-standing HIV treatment infrastructure and research experience, making it important for prevention, treatment, and implementation studies in Latin America, while Mexico supports regional recruitment relevance through urban HIV care networks and cross-border public health considerations.

Actionable Recommendations for HIV Clinical Trial Leaders

Industry leaders should prioritize inclusive protocol design, scientifically justified enrollment of underrepresented populations, and early engagement with community advisory groups to improve trust, recruitment, and retention. Trial sponsors and investigators should align endpoints with real-world HIV care needs, including adherence, acceptability, resistance outcomes, drug-drug interactions, pregnancy safety, and durability of response. Decentralized trial tools should be deployed selectively, with strong safeguards for privacy, digital literacy, and participant confidentiality. Leaders should invest in regional site readiness, laboratory quality systems, staff training, and ethical review capacity, especially in high-burden regions where research participation must be matched with post-trial access planning. AI-enabled tools should be validated across diverse populations before operational use, and governance frameworks should address bias, explainability, cybersecurity, and compliance with data protection rules. Strategic partnerships with public health programs, community organizations, and regulatory stakeholders can improve feasibility while supporting trial designs that are scientifically rigorous, socially responsible, and operationally resilient.

Research Methodology for Evidence-Based HIV Clinical Trial Insights

This executive summary is developed through a structured secondary research approach using verified public health, regulatory, scientific, and clinical trial information sources. The methodology includes review of global HIV epidemiology from recognized public health agencies, analysis of clinical trial registry patterns, assessment of regulatory guidance on clinical research conduct, and synthesis of peer-reviewed literature related to antiretroviral development, HIV prevention, vaccine research, immune-based therapies, and cure-directed approaches. Regional, group, and country insights are interpreted through documented indicators such as disease burden, clinical research infrastructure, regulatory maturity, public health program capacity, and representation of key populations. The analysis excludes market sizing, market share, revenue estimation, and forecasting, focusing instead on evidence-based qualitative trends, scientific priorities, operational dynamics, and policy-relevant developments shaping HIV clinical trials.

Conclusion on the Future of HIV Clinical Trials

HIV clinical trials are advancing through a convergence of biomedical innovation, digital transformation, regulatory evolution, and stronger community-centered research practices. The field is moving beyond conventional treatment comparisons toward long-acting prevention, differentiated delivery, immunological interventions, and cure-oriented strategies that require sophisticated trial designs and diverse participant representation. Regional participation is broadening, with high-burden settings, advanced research economies, and emerging clinical research hubs each contributing essential evidence. Artificial intelligence and decentralized technologies can improve efficiency and precision, but their value depends on ethical governance, inclusivity, and validated performance across populations affected by HIV. The next phase of HIV clinical research will be defined by the ability of stakeholders to combine scientific rigor with equity, operational adaptability, and sustained commitment to participant trust and public health impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. HIV Clinical Trials Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Entry Inhibitors
    • 7.2.1. Enfuvirtide
    • 7.2.2. Maraviroc
  • 7.3. Integrase Strand Transfer Inhibitors
    • 7.3.1. Bictegravir
    • 7.3.2. Dolutegravir
    • 7.3.3. Elvitegravir
    • 7.3.4. Raltegravir
  • 7.4. Non-Nucleoside Reverse Transcriptase Inhibitors
    • 7.4.1. Efavirenz
    • 7.4.2. Etravirine
    • 7.4.3. Nevirapine
    • 7.4.4. Rilpivirine
  • 7.5. Nucleoside Reverse Transcriptase Inhibitors
    • 7.5.1. Emtricitabine
    • 7.5.2. Lamivudine
    • 7.5.3. Tenofovir
    • 7.5.4. Zidovudine
  • 7.6. Protease Inhibitors
    • 7.6.1. Atazanavir
    • 7.6.2. Darunavir
    • 7.6.3. Fosamprenavir
    • 7.6.4. Lopinavir

8. HIV Clinical Trials Market, by Trial Phase

  • 8.1. Introduction
  • 8.2. Phase I
  • 8.3. Phase II
    • 8.3.1. Phase IIa
    • 8.3.2. Phase IIb
  • 8.4. Phase III
  • 8.5. Phase IV

9. HIV Clinical Trials Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Injectable
  • 9.3. Oral
  • 9.4. Transdermal

10. HIV Clinical Trials Market, by Patient Age Group

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Geriatric
  • 10.4. Pediatric

11. HIV Clinical Trials Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Hospitals
  • 11.4. Research Institutes
    • 11.4.1. Academic Institutes
    • 11.4.2. Contract Research Organizations

12. HIV Clinical Trials Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Offline
  • 12.3. Online

13. HIV Clinical Trials Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. HIV Clinical Trials Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. HIV Clinical Trials Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. American Gene Technologies International Inc.
  • 17.3. Assembly Biosciences, Inc.
  • 17.4. BioNTech SE
  • 17.5. Bristol-Myers Squibb Company
  • 17.6. Charles River Laboratories International, Inc.
  • 17.7. CytoDyn Inc.
  • 17.8. Excision BioTherapeutics, Inc.
  • 17.9. Frontier Biotechnologies Inc.
  • 17.10. GeoVax Labs, Inc.
  • 17.11. Gilead Sciences, Inc.
  • 17.12. IAVI
  • 17.13. ICON plc
  • 17.14. International AIDS Vaccine Initiative, Inc.
  • 17.15. IQVIA Holdings Inc.
  • 17.16. Johnson & Johnson
  • 17.17. Labcorp Drug Development Inc.
  • 17.18. Medpace Holdings, Inc.
  • 17.19. Merck & Co., Inc.
  • 17.20. Moderna, Inc.
  • 17.21. Novotech Health Holdings Pte. Ltd.
  • 17.22. Parexel International Corporation
  • 17.23. PPD, Inc.
  • 17.24. Shanghai Henlius Biotech, Inc.
  • 17.25. Syneos Health, Inc.
  • 17.26. TaiMed Biologics Inc.
  • 17.27. Theratechnologies Inc.
  • 17.28. ViiV Healthcare Limited
  • 17.29. Vir Biotechnology, Inc.
  • 17.30. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HIV CLINICAL TRIALS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HIV CLINICAL TRIALS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HIV CLINICAL TRIALS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HIV CLINICAL TRIALS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL HIV CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL HIV CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL HIV CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENFUVIRTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENFUVIRTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENFUVIRTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MARAVIROC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MARAVIROC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MARAVIROC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BICTEGRAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BICTEGRAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BICTEGRAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DOLUTEGRAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DOLUTEGRAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DOLUTEGRAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ELVITEGRAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ELVITEGRAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ELVITEGRAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RALTEGRAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RALTEGRAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RALTEGRAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EFAVIRENZ MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EFAVIRENZ MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EFAVIRENZ MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ETRAVIRINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ETRAVIRINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ETRAVIRINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEVIRAPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEVIRAPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEVIRAPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RILPIVIRINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RILPIVIRINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RILPIVIRINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EMTRICITABINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EMTRICITABINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EMTRICITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LAMIVUDINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LAMIVUDINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LAMIVUDINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TENOFOVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TENOFOVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TENOFOVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ZIDOVUDINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ZIDOVUDINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ZIDOVUDINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ATAZANAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ATAZANAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ATAZANAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DARUNAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DARUNAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DARUNAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FOSAMPRENAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FOSAMPRENAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FOSAMPRENAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LOPINAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LOPINAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LOPINAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PHASE IIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHASE IIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PHASE IIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PHASE IIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PHASE IIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PHASE IIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHASE IV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PHASE IV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHASE IV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. NATO HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. NATO HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 224. NATO HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 225. NATO HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 228. NATO HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 229. NATO HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 230. NATO HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. NATO HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. NATO HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 234. NATO HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. G7 HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. G7 HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 238. G7 HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 241. G7 HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 242. G7 HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 243. G7 HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 244. G7 HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. G7 HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. G7 HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. G7 HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 248. G7 HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. GCC HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 292. GCC HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 293. GCC HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 294. GCC HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 295. GCC HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 296. GCC HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 297. GCC HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 298. GCC HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 299. GCC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 300. GCC HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 301. GCC HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 302. GCC HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. GCC HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 304. GCC HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 334. JAPAN HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 336. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 337. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 338. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 339. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 340. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 341. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 342. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 343. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 344. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 345. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 346. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 347. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 348. INDIA HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 349. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 350. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 351. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 352. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSI